CA
NZ
UK
AU
IND
US
…
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Alumis Inc (NASDAQ: ALMS) has limited public disclosures, so its core business and product lines are not clearly documented. Investors should monitor filings and company updates for confirmation of long-term growth drivers such as commercializing technologies, entering new markets, or forming strategic partnerships. The company may attract investors seeking upside from execution of disclosed initiatives, conditional on improved transparency.
Principal risks include limited transparency, execution and financing risk for early-stage initiatives, possible lack of consistent revenue or profitability, and regulatory or market uncertainty.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Income before tax | -251.89M | -294.23M | -154.99M | -111.93M |
| Net income | -243.32M | -294.23M | -154.99M | -111.93M |
| Selling general administrative | 91.86M | 35.20M | 20.50M | 12.55M |
| Gross profit | 20.55M | -3.15M | -1.28M | -0.25M |
| Reconciled depreciation | 3.50M | 3.15M | 1.28M | 0.25M |
| Ebit | -427.20M | -300.75M | -158.17M | -113.85M |
| Ebitda | -423.71M | -297.60M | -156.89M | -113.60M |
| Depreciation and amortization | 3.50M | 3.15M | 1.28M | 0.25M |
| Operating income | -427.20M | -300.75M | -158.17M | -113.85M |
| Other operating expenses | 451.25M | 300.75M | 158.17M | 113.85M |
| Tax provision | -8.56M | 0.00M | - | - |
| Interest income | 14.18M | 12.02M | 3.37M | 1.99M |
| Net interest income | 14.18M | 12.02M | 3.37M | 1.99M |
| Income tax expense | -8.56M | - | - | - |
| Total revenue | 24.05M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 447.76M | 297.60M | 158.17M | 113.60M |
| Cost of revenue | 3.50M | 3.15M | 1.28M | 0.25M |
| Total other income expense net | 175.32M | 6.52M | 3.18M | 1.92M |
| Net income from continuing ops | -243.32M | -294.23M | -154.99M | -111.93M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Total assets | 411.94M | 340.99M | 89.61M | 108.17M |
| Intangible assets | 50.96M | - | - | - |
| Other current assets | 7.65M | 16.11M | 3.79M | 8.98M |
| Total liab | 110.64M | 80.89M | 53.50M | 17.94M |
| Total stockholder equity | 301.30M | 260.10M | 36.11M | 90.23M |
| Other current liab | 57.08M | 39.73M | 18.03M | 10.32M |
| Common stock | 0.01M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.01M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -901.88M | -658.55M | -364.32M | -209.32M |
| Other assets | - | - | 0.00M | - |
| Cash | 89.67M | 169.53M | 46.00M | 25.82M |
| Total current liabilities | 73.32M | 50.91M | 20.87M | 13.35M |
| Current deferred revenue | 1.46M | - | -1.12M | -1.72M |
| Net debt | -52.76M | -138.80M | -13.42M | -24.04M |
| Short term debt | 4.67M | 1.56M | 1.72M | 1.31M |
| Short long term debt total | 36.91M | 30.72M | 32.58M | 1.78M |
| Other stockholder equity | 1202.97M | 918.61M | 25.05M | 14.21M |
| Total current assets | 318.23M | 306.19M | 53.36M | 102.56M |
| Short term investments | 218.83M | 118.74M | 2.96M | 67.25M |
| Net receivables | 2.08M | 1.81M | 0.61M | 0.50M |
| Accounts payable | 10.11M | 9.62M | 1.12M | 1.72M |
| Accumulated other comprehensive income | 0.19M | 0.04M | 0.00M | -0.13M |
| Non currrent assets other | 7.59M | 1.11M | 0.01M | 1.14M |
| Non current assets total | 93.71M | 34.80M | 36.26M | 5.61M |
| Capital lease obligations | 36.91M | 30.72M | 32.58M | 1.78M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Investments | 238.79M | -113.79M | 60.47M | -68.75M |
| Total cashflows from investing activities | 287.88M | -113.79M | - | - |
| Total cash from financing activities | 2.07M | 492.37M | 89.68M | 101.63M |
| Net income | -243.32M | -294.23M | -154.99M | -111.93M |
| Change in cash | -79.58M | 123.50M | 20.18M | -75.98M |
| Begin period cash flow | 170.63M | 47.13M | 26.95M | 101.80M |
| End period cash flow | 91.05M | 170.63M | 47.13M | 25.82M |
| Total cash from operating activities | -369.52M | -255.08M | -129.97M | -107.72M |
| Issuance of capital stock | 0.00M | 451.78M | 89.78M | 99.89M |
| Depreciation | 3.50M | 3.15M | 1.28M | 0.25M |
| Other cashflows from investing activities | 49.74M | - | - | - |
| Sale purchase of stock | -0.02M | - | -0.06M | - |
| Other cashflows from financing activities | - | 299.05M | 89.68M | 101.63M |
| Capital expenditures | 0.65M | 1.73M | 4.50M | 2.41M |
| Change in working capital | 26.32M | 14.76M | 12.06M | -1.92M |
| Stock based compensation | 43.52M | 19.46M | 8.62M | 5.96M |
| Other non cash items | -190.97M | 1.79M | 3.05M | 6.37M |
| Free cash flow | -370.18M | -256.81M | -134.47M | -110.13M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
|---|---|---|---|---|---|---|---|
| ALMS Alumis Inc |
-0.35 5.20% |
6.38 | - | - | 130.69 | 10.55 | 120.88 |
| NVO Novo Nordisk A/S |
0.45 1.12% |
40.45 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 |
| VRTX Vertex Pharmaceuticals Inc |
-5.73 1.03% |
553.15 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 |
| REGN Regeneron Pharmaceuticals Inc |
33.37 3.60% |
961.26 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 |
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
280 East Grand Avenue, South San Francisco, CA, United States, 94080
650 231 6625
221
| Name | Title | Year Born |
|---|---|---|
| Mr. Martin Babler Ph.D. | President, CEO & Chairman | 1965 |
| Dr. David M. Goldstein Ph.D. | Chief Scientific Officer | 1966 |
| Mr. Roy C. Hardiman J.D. | Chief Business Officer | 1960 |
| Mr. John R. Schroer C.F.A. | Chief Financial Officer | 1965 |
| Ms. Sara Klein | Chief Legal Officer & Corporate Secretary | 1964 |
| Ms. Claire Langrish Ph.D. | Senior VP & Head of Immunology and Translational Science | NA |
| Mr. Philip Nunn Ph.D. | Senior VP of Pharmacology & Project Team Leader | NA |
| Dr. Jorn Drappa M.D., Ph.D. | Chief Medical Officer | 1964 |
| Mr. Mark Bradley | Chief Development Officer | 1965 |
| Mr. Kolbot By Ph.D. | Senior VP & Head of Technical Operations | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.09%
Communication Services
+0.21%
Consumer Cyclical
+1.14%
Consumer Defensive
+0.88%
Energy
-2.61%
Financial Services
+0.70%
Financials
+0.41%
Healthcare
-0.75%
Industrials
+0.35%
Real Estate
+0.57%
Technology
-1.17%
Utilities
+0.05%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...